Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

MicroRNAs (miRs) are small noncoding RNAs that function as post-transcriptional regulators of gene expression and have important roles in almost all biological pathways. Deregulated miR expression has been detected in numerous cancers, where miRs act as both oncogene and tumor suppressors. Due to their important roles in tumorigenesis, miRs have been investigated as prognostic and diagnostic biomarkers and as useful targets for therapeutic intervention. From a therapeutic point of view, two modalities can serve to rectify gene networks in cancer cells. For oncomiRs, a rational means is downregulation through antagomirs. Moreover, observations of the pathological reductions in tumor-suppressive miRs have inspired the concept of “miR replacement therapy” to enhance the amount of these miRs, thereby restoring them to normal levels. However, the clinical applicability of miR-based therapies is severely limited by the lack of effective delivery systems. Therefore, to understand the role of this new class of regulators, we need to identify the mRNA targets regulated by individual miRs as well as to develop specific, efficient, and safe delivery systems for therapeutic miRs.

Breast cancer --- Hypoxia inducible factor 1-alpha (HIF-1α) --- MicroRNA (miRNA) --- miR526b --- miR655 --- Oxidative stress --- Migration --- Cyclooxygenase-2 (COX-2) --- Prostaglandin E2 receptor 4 (EP4) --- PI3K/Akt --- adipokines --- endometrial cancer --- estrogens --- hyperinsulinemia --- insulin --- insulin resistance --- insulin signaling --- insulin-like growth factors --- microRNA --- miRNA --- ovarian cancer --- survival --- prognostic factor --- serum LDH --- blood biomarker --- circulating microRNA --- plasma --- immunotherapy --- immune checkpoint inhibitors --- metastatic melanoma --- hepatocellular carcinoma --- metastasis --- exosome --- bioinformatics analysis --- renal cancer --- RCC --- ccRCC --- meta-analysis --- miRNAs --- normal B-cell development --- B-CLL --- miRNA-transcription factor network --- regulation --- biomarker --- therapy --- prognosis --- diagnosis --- progression --- prediction --- smoking --- non-small cell lung cancer --- methylation --- miR-584-5p --- YKT6 --- snoRNA --- 2′-O-methylation --- pseudouridylation --- malignant melanoma --- cancer stem cell --- stemness --- head and neck squamous cell carcinoma --- colon cancer --- cancer stem cells --- microRNAs --- deformability --- PARP --- replication stress --- targeted therapy --- breast cancer --- circulating biomarkers --- medulloblastoma --- brain tumour --- subgroups --- stem cells --- n/a --- 2'-O-methylation

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book includes some recent works providing the readers with novel relevant findings about the main signaling pathways that govern the molecular pathogenesis of some of the highest prevalent human tumors, which are the basis for developing alternative therapeutic strategies to improve patient outcomes.

Medicine --- Oncology --- actin cytoskeletal reorganization --- breast cancer --- CD99 agonist --- EGFR dimerization --- endocytosis --- FAK dephosphorylation --- PTPN12 --- Rac1 --- RhoA --- tripeptide --- OMD --- PRELP --- tumor suppression gene --- bladder cancer initiation --- tight junction --- partial EMT --- tousled-like kinase (TLK) --- NIMA-related kinase 1 (NEK1) --- yes-associated protein 1 (YAP1) --- thioridazine (THD) --- MS-determined phosphopeptides --- human immunodeficiency virus type 1 --- epithelial cells --- carcinogenicity --- oxidative stress --- reactive oxygen species --- gp120 --- Tat --- Nef --- matrix protein p17 --- reverse transcriptase --- mitochondria --- metastasis --- OXPHOS --- cancer --- Warburg effect --- cancer therapeutics --- myeloproliferative neoplasms --- signaling pathways --- JAK2 --- CALR --- MPL --- TPOR --- DUSP1 --- MAPK --- Snail --- prostate cancer --- migration and invasion --- patient survival --- biomarkers --- pBRD4 --- SET --- PP2A --- prognosis --- triple negative breast cancer --- resistance --- anti-receptor therapy --- trastuzumab --- PI3K --- mTOR --- TAK-228 --- epigenetic --- methylation --- acetylation --- non-coding RNA --- small-cell lung cancer --- triple-negative breast cancer --- pancreatic ductal adenocarcinoma --- glioblastoma --- metastatic melanoma --- advanced ovarian cancer --- hepatocellular carcinoma --- immune evasion --- immunotherapy --- immune checkpoint inhibitors --- oncogenic signaling pathway --- molecular targeted agents --- genome --- epigenome --- tumor immune microenvironment --- ovarian cancer --- adaptive immunity --- innate immunity --- complement system --- cancer immunology --- tumor microenvironment --- splicing pathway --- luminal breast cancer --- BET inhibitors --- actin cytoskeletal reorganization --- breast cancer --- CD99 agonist --- EGFR dimerization --- endocytosis --- FAK dephosphorylation --- PTPN12 --- Rac1 --- RhoA --- tripeptide --- OMD --- PRELP --- tumor suppression gene --- bladder cancer initiation --- tight junction --- partial EMT --- tousled-like kinase (TLK) --- NIMA-related kinase 1 (NEK1) --- yes-associated protein 1 (YAP1) --- thioridazine (THD) --- MS-determined phosphopeptides --- human immunodeficiency virus type 1 --- epithelial cells --- carcinogenicity --- oxidative stress --- reactive oxygen species --- gp120 --- Tat --- Nef --- matrix protein p17 --- reverse transcriptase --- mitochondria --- metastasis --- OXPHOS --- cancer --- Warburg effect --- cancer therapeutics --- myeloproliferative neoplasms --- signaling pathways --- JAK2 --- CALR --- MPL --- TPOR --- DUSP1 --- MAPK --- Snail --- prostate cancer --- migration and invasion --- patient survival --- biomarkers --- pBRD4 --- SET --- PP2A --- prognosis --- triple negative breast cancer --- resistance --- anti-receptor therapy --- trastuzumab --- PI3K --- mTOR --- TAK-228 --- epigenetic --- methylation --- acetylation --- non-coding RNA --- small-cell lung cancer --- triple-negative breast cancer --- pancreatic ductal adenocarcinoma --- glioblastoma --- metastatic melanoma --- advanced ovarian cancer --- hepatocellular carcinoma --- immune evasion --- immunotherapy --- immune checkpoint inhibitors --- oncogenic signaling pathway --- molecular targeted agents --- genome --- epigenome --- tumor immune microenvironment --- ovarian cancer --- adaptive immunity --- innate immunity --- complement system --- cancer immunology --- tumor microenvironment --- splicing pathway --- luminal breast cancer --- BET inhibitors

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book includes some recent works providing the readers with novel relevant findings about the main signaling pathways that govern the molecular pathogenesis of some of the highest prevalent human tumors, which are the basis for developing alternative therapeutic strategies to improve patient outcomes.

actin cytoskeletal reorganization --- breast cancer --- CD99 agonist --- EGFR dimerization --- endocytosis --- FAK dephosphorylation --- PTPN12 --- Rac1 --- RhoA --- tripeptide --- OMD --- PRELP --- tumor suppression gene --- bladder cancer initiation --- tight junction --- partial EMT --- tousled-like kinase (TLK) --- NIMA-related kinase 1 (NEK1) --- yes-associated protein 1 (YAP1) --- thioridazine (THD) --- MS-determined phosphopeptides --- human immunodeficiency virus type 1 --- epithelial cells --- carcinogenicity --- oxidative stress --- reactive oxygen species --- gp120 --- Tat --- Nef --- matrix protein p17 --- reverse transcriptase --- mitochondria --- metastasis --- OXPHOS --- cancer --- Warburg effect --- cancer therapeutics --- myeloproliferative neoplasms --- signaling pathways --- JAK2 --- CALR --- MPL --- TPOR --- DUSP1 --- MAPK --- Snail --- prostate cancer --- migration and invasion --- patient survival --- biomarkers --- pBRD4 --- SET --- PP2A --- prognosis --- triple negative breast cancer --- resistance --- anti-receptor therapy --- trastuzumab --- PI3K --- mTOR --- TAK-228 --- epigenetic --- methylation --- acetylation --- non-coding RNA --- small-cell lung cancer --- triple-negative breast cancer --- pancreatic ductal adenocarcinoma --- glioblastoma --- metastatic melanoma --- advanced ovarian cancer --- hepatocellular carcinoma --- immune evasion --- immunotherapy --- immune checkpoint inhibitors --- oncogenic signaling pathway --- molecular targeted agents --- genome --- epigenome --- tumor immune microenvironment --- ovarian cancer --- adaptive immunity --- innate immunity --- complement system --- cancer immunology --- tumor microenvironment --- splicing pathway --- luminal breast cancer --- BET inhibitors --- n/a